Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Nov 6;12(31):6425-6427.
doi: 10.12998/wjcc.v12.i31.6425.

Refractory ulcerative colitis: Upadacitinib versus other biologics

Said G Farhat  1   2 , Jessy G Fadel  1
Affiliations
Editorial

Refractory ulcerative colitis: Upadacitinib versus other biologics

Said G Farhat et al. World J Clin Cases. .

Abstract

In this editorial we comment on an article published in World Journal of Clinical Cases in 2024, in which a case of refractory ulcerative colitis (UC) was discussed based on the response to different lines of biologics. Different studies showed that different classes of biologics have their advantages and disadvantages in the treatment of refractory UC. Certain classes are superior to others and if tried earlier on would lead to a possible change in the outcome.

Keywords: Refractory; Ulcerative colitis; Upadacitinib; Ustekinumab; Vedolizumab.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.

Similar articles

See all similar articles

References

    1. Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol. 2015;21:8776–8786. - PMC - PubMed
    1. Reinisch W, Tran J, Patel K, Borruel N, Melmed GY, Wegrzyn L, Levy G, Ilo D, Sanchez Gonzalez Y, Panaccione R. Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison. J Crohns Colitis. 2023;17:i785–i786.
    1. Xu X, Jiang JW, Lu BY, Li XX. Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: A case report. World J Clin Cases. 2024;12:1685–1690. - PMC - PubMed
    1. Dalal RS, Kallumkal G, Cabral HJ. Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis at 8-16 Weeks: A Multicenter Retrospective Cohort Study. Gastroenterol Hepatol (NY) 2023;19:3–4. - PMC - PubMed
    1. Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020;158:562–572.e12. - PubMed

Publication types

LinkOut - more resources